A multicenter study (Sereno et al., 2021) suggested that prolonged granulocyte-colony stimulating factor (G-CSF) treatment was associated with a worse outcome in cancer patients with neutropenia and COVID-19. This evidence concerns the gene CSF3 and COVID-19.